Skip to Content

Ondansetron Hydrochloride Injection

Last Updated: March 9, 2018
Status: Current

Ondansetron Hydrochloride Injection

Products Affected - Description
  • Zofran injection, Novartis
    2 mg/mL, 20 mL vial, 1 count (NDC 00173-0442-00)

 
Ondansetron injection, Apotex
2 mg/mL, 2 mL vial, 25 count (NDC 60505-6130-05)
 
Ondansetron injection, AuroMedics
2 mg/mL, 2 mL vial, 25 count (NDC 55150-0125-02)
2 mg/mL, 20 mL vial, 1 count (NDC 55150-0126-20)
 
Ondansetron injection, Heritage
2 mg/mL, 2 mL vial, 10 count (NDC 23155-0547-41)
2 mg/mL, 2 mL vial, 25 count (NDC 23155-0547-42)
2 mg/mL, 20 mL vial, 1 count (NDC 23155-0549-31)
 
Ondansetron injection, Mylan Institutional
2 mg/mL, 2 mL vial, 25 count (NDC 67457-0441-20)
2 mg/mL, 20 mL vial, 1 count (NDC 67457-0440-20)
 
Ondansetron injection, Pfizer
2 mg/mL, 2 mL iSecure syringe, 10 count (NDC 00409-1120-12)
2 mg/mL, 2 mL vial, 25 count (NDC 00409-4755-03)
 
Ondansetron injection, Sagent
2 mg/mL, 2 mL vial, 25 count (NDC 25021-0777-02)

Ondansetron injection, West-Ward
2 mg/mL, 2 mL vial, 25 count (NDC 00641-6078-25)
Reason for the Shortage
    • Apotex did not provide a reason for the shortage.
    • Athenex has ondansetron injection available.
    • AuroMedics did not provide a reason for the shortage.
    • Fresenius Kabi has ondansetron injection available.
    • Heritage has ondansetron on shortage due to increased demand.
    • Mylan Institutional did not provide a reason for the shortage.
    • Pfizer has ondansetron injection on shortage due to manufacturing delays.
    • Sagent did not provide a reason for the shortage.
    • West-Ward did not provide a reason for the shortage.
    • Novartis did not provide a reason for the shortage.
Available Products
  • Ondansetron injection, Athenex
    2 mg/mL, 2 mL vial, 25 count (NDC 70860-0776-02)
    2 mg/mL, 20 mL vial, 1 count (NDC 70860-0777-20)


Ondansetron injection, Fresenius Kabi
2 mg/mL, 2 mL prefilled syringe, 24 count (NDC 76045-0103-20)
2 mg/mL, 2 mL vial, 25 count (NDC 63323-0373-02)
2 mg/mL, 20 mL vial, 1 count (NDC 63323-0374-20)
 
Ondansetron injection, Pfizer
2 mg/mL, 20 mL vial, 1 count (NDC 00409-4759-01)
 
Ondansetron injection, Sagent
2 mg/mL, 20 mL vial, 1 count (NDC 25021-0782-20)
 
Ondansetron injection, West-Ward
2 mg/mL, 20 mL vial, 1 count (NDC 00641-6079-01)
2 mg/mL, 20 mL vial, 1 count (NDC 00143-9890-01)

Estimated Resupply Dates

    • Apotex has ondansetron 2 mg/mL 2 mL vials on back order and the company estimates a release date of mid-March 2018.
    • AuroMedics has ondansetron 2 mg/mL 2 mL and 20 mL vials on intermittent back order and the company is releasing product as it becomes available.
    • Heritagen has all ondansetron presentations on allocation.
    • Mylan Institutional has ondansetron 2 mg/mL 2 mL and 20 mL vials on back order and the company estimates a release date of mid-April 2018 for the 2 mL vials and early-April 2018 for the 20 mL vials.
    • Pfizer has ondansetron 2 mg/mL 2 mL vials on back order and the company estimates a release date of late-March 2018. The 2 mg/mL 2 mL iSecure syringes are on back order and the company estimates a release date of June 2019.
    • Sagent has ondansetron 2 mg/mL 2 mL vials on back order and the company cannot estimate a release date.
    • West-Ward has ondansetron 2 mg/mL 2 mL vials on back order and the company estimates a release date of March 2018.
    • Novartis has Zofran 2 mg/mL 20 mL vials on back order and the company cannot estimate a release date.

Updated

March 9 and 8, 2018, University of Utah, Drug Information Service. Copyright 2018, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide